Mexican health authorities announced the authorization of lenacapavir for pre-exposure prophylaxis (PrEP) against the human immunodeficiency virus (HIV). The medication is long-acting and will be administered via subcutaneous injection twice a year.
The drug's registration was confirmed last week…
Read More...
